Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· January 15, 2026

Fortuna Achieves 2025 Production Guidance, Delivering 317,001 GEO, and Issues 2026 Outlook

View original at globenewswire.com
Fortuna Achieves 2025 Production Guidance, Delivering 317,001 GEO, and Issues 2026 Outlook VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Fortuna Mining Corp…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Corporate target of 500,000 oz gold annually

    80% confidence

  • Diamba Sud PEA shows robust economics

    80% confidence

  • TRIFR improved to 0.74 in 2025 from 1.36 in 2024

    80% confidence

  • Preliminary unaudited liquidity of $704 million and net cash position of $382 million as of December 31, 2025

    80% confidence

  • Caylloma achieving 100% renewable energy from national grid

    80% confidence

  • Séguéla expansion targeting over 200,000 oz/year production

    80% confidence

  • Lindero produced 87,489 oz gold in 2025, 6% below lower guidance of 93,000 oz due to Q4 mechanical downtime

    80% confidence

  • Séguéla achieved record gold production of 152,426 oz, 4% above guidance upper end of 147,000 oz

    80% confidence

  • 2026 production guidance of 281,000-305,000 GEO represents 1-9% increase versus 2025

    80% confidence

  • Achieved 2025 production guidance of 317,001 GEO within range of 309,000-339,000 GEO

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com